3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
2
Urinary Bladder Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
Urine Specimen Collection
×
Clear all
NCT05151341
2025-07-24
URODX-FGFR3
Institut de Cancérologie de Lorraine
Phase NA
Completed
190 enrolled